

# EIREF-C

Pantoprazole 40 mg and Cinitapride 3 mg SR Capsules



**THE FIRE FIGHTER**

# EIREF-C

Pantoprazole 40 mg and Cinitapride 3 mg SR Capsules

## INTRODUCTION:

Gastroesophageal Reflux Disease (GERD) and Functional Dyspepsia (FD) are the two most prevalent upper gastrointestinal disorders. A number of pathophysiological factors are common to GERD and functional dyspepsia.<sup>1</sup> The prevalence of GERD in India ranges from 7.6% to 30%.<sup>2</sup>

## CLINICAL EVIDENCE:

### 1 EFFICACY AND SAFETY OF CINITAPRIDE IN FUNCTIONAL DYSPEPSIA

Vol. 63, No. 6, June 2013

**No. of Patients:** 121 (Patients >18 years of age)

**Duration:** 4 Weeks

**Dose:** Cinitapride 1mg thrice daily 15 minutes before meal

**Result:**




Fig: Efficacy measured by Global Dyspepsia Index

Baseline Global Dyspepsia Index (GDI) was  $13.02 \pm 6.31$ . At the end of four weeks the GDI came down to  $6.65 \pm 4.05$  ( $p < 0.0001$ ).




Fig: Improvement in quality of life

A marked improvement from baseline values

$32.98 \pm 8.36$  to  $26.61 \pm 6.65$  ( $p < 0.01$ ) at week 2 and at week 4 and further improved to  $19.81 \pm 5.82$  ( $p < 0.01$ ).

## CONCLUSION:

Cinitapride is effective in minimising dyspepsia symptoms, and improving the quality of life of patients. It is well tolerated and almost free of side effects.



## 2 ORAL PANTOPRAZOLE FOR EROSIVE ESOPHAGITIS


AJG – Vol. 95, No. 11, 2000

**No. of Patients:** 603 patients (Patients ≥ 18 years of age)


**Duration:** 8 Weeks

**Dose:** Pantoprazole (10 mg, 20 mg, or 40 mg) or placebo, OD in the morning.

**Result:**



Endoscopic healing rates: percentage (%) of patients healed after 4 and 8 week according to treatment regimen.



Percentage (%) of patients healed according to initial disease severity.  
Endoscopic healing rates shown by treatment regimen after 4 and 8 weeks of treatment.

### CONCLUSION:

The pantoprazole 40 mg produces a significantly greater healing rate than either 10 or 20 mg of pantoprazole ( $p \leq 0.001$  vs pantoprazole 10 mg and 20 mg).

### CINITAPRIDE IN EIREF-C:

- ① Cinitapride is a gastroprokinetic/gastrointestinal promotility drug and antiulcer agent of the benzamide class.
- ② It is metabolized by both cytochrome P450 (CYP) 3A4 enzyme and CYP2C8. Because of that the risk of drug interaction is lower.<sup>3</sup>
- ③ The free drug concentration of cinitapride is much lower than that of cisapride and domperidone, resulting in a lower risk of cardiotoxicity.<sup>3</sup>

### PANTOPRAZOLE IN EIREF-C:

- ① Pantoprazole, a substituted benzimidazole, inhibits the final step of gastric acid production.<sup>4</sup>
- ② Pantoprazole exhibits the lowest acid activation at less acidic pH.<sup>4</sup>
- ③ It is approved by the FDA for the treatment of erosive esophagitis associated with GERD.



# EIREF-C

Pantoprazole 40 mg and Cinitapride 3 mg SR Capsules

## DESCRIPTION:

EIREF-C contains Cinitapride in combination with Pantoprazole in the strength of 3 mg + 40 mg and available as hard gelatin capsule.

## INDICATIONS:

In the treatment of patients suffering from Non-Ulcer Dyspepsia (NUD) or Gastroesophageal Reflux Disease (GERD).

## MECHANISM OF ACTION:

### CINITAPRIDE:

- ◆ Cinitapride is a gastroprokinetic and antiulcer benzamide with agonist activity at 5-HT<sub>1</sub> and 5-HT<sub>4</sub> receptors and antagonist activity at 5-HT<sub>2</sub> receptors. It blocks the presynaptic serotonin receptors and increases its release, resulting in greater serotonergic activity.

### PANTOPRAZOLE:

- ◆ Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells.
- ◆ Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H<sup>+</sup>K<sup>+</sup>-ATPase enzyme, i.e. the final stage in the production of hydrochloric acid in the stomach.

## DOSAGE AND ADMINISTRATION:

- ◆ The recommended dose is 1 capsule once daily or as directed by the Physician.
- ◆ Method of administration: For oral administration only. The capsules should not be chewed or crushed, and should be swallowed whole 1 hour before a meal with some water.

## STORAGE:

Store protected from light and moisture at a temperature not exceeding 30°C

## PRESENTATION:

EIREF-C is available as 10 capsules in a strip.

### Reference:

1. Nat. Rev. Gastroenterol. Hepatol. 10, 175–186 (2013)
2. Indian Society of Gastroenterology 2019
3. ADRJ, February 2019, Vol 21 . No. 1
4. AJG – Vol. 95, No. 11, 2000



## La Renon Healthcare Private Limited

207-208 ISCON Elegance, Circle P, Prahlad Nagar Cross Roads,  
S.G. Highway, Ahmedabad- 380015, Gujarat, India.  
Phone: +91-79-6616-8998, 2693-6656 | E-mail: info@larenon.com  
Web: www.larenon.com

I am: \_\_\_\_\_  
Call me on: \_\_\_\_\_  
Mail me at: \_\_\_\_\_

©2022 All rights reserved, La Renon Healthcare Private Limited